CMV after hematopoietic stem cell transplantation: Difference between revisions
From IDWiki
(Created page with "== Management == * Most frequently managed with weekly viral loads and preemptive treatment (PET) at a lab-specific threshold * Treatment is typically with Is treated by::va...") |
(fixed treatment) |
||
| Line 1: | Line 1: | ||
== Management == |
== Management == |
||
* Most frequently managed with weekly viral loads and preemptive treatment (PET) at a lab-specific threshold |
* Most frequently managed with weekly viral loads and preemptive treatment (PET) at a lab-specific threshold |
||
* Antiviral treatment: |
|||
* Treatment is typically with [[Is treated by::valganciclovir]] 900 mg po daily, but may need [[Is treated by::ganciclovir]] 5 mg/kg IV if no oral access, or [[Is treated by::foscarnet]] 90 mg/kg IV q12h followed by q24h if resistance is suspected |
|||
** [[Is treated by::ganciclovir]] 5 mg/kg q12h for 7 to 14 days (induction) followed by [[Is treated by::valganciclovir]] 900 mg po daily (maintenance) until a few weeks after viremia resolves |
|||
** If concerns about oral antiviral, would continue [[Is treated by::ganciclovir]] 5 mg/kg IV daily (maintenance) |
|||
** If ganciclovir resistance, next step is [[Is treated by::foscarnet]] 90 mg/kg IV q12h (induction) followed by q24h (maintenance) |
|||
** Major adverse effect of ganciclovir is bone marrow suppression |
|||
* Use CMV safe (leukoreduced or filtered) blood products if the recipient is CMV seronegative |
* Use CMV safe (leukoreduced or filtered) blood products if the recipient is CMV seronegative |
||
Revision as of 01:21, 7 March 2020
Management
- Most frequently managed with weekly viral loads and preemptive treatment (PET) at a lab-specific threshold
- Antiviral treatment:
- ganciclovir 5 mg/kg q12h for 7 to 14 days (induction) followed by valganciclovir 900 mg po daily (maintenance) until a few weeks after viremia resolves
- If concerns about oral antiviral, would continue ganciclovir 5 mg/kg IV daily (maintenance)
- If ganciclovir resistance, next step is foscarnet 90 mg/kg IV q12h (induction) followed by q24h (maintenance)
- Major adverse effect of ganciclovir is bone marrow suppression
- Use CMV safe (leukoreduced or filtered) blood products if the recipient is CMV seronegative
| Serostatus | Blood products | Duration of PET |
|---|---|---|
| D-/R- | CMV safe | weeks 2 to 12 |
| D+/R- | CMV safe | weeks 2 to 12 |
| autologous R- | CMV safe | weeks 2 to 5 |
| D±/R+ | CMV untested | weeks 2 to 12, then q2-4wk until week 26 |
| autologous R+ | CMV untested | weeks 2 to 5 |
